Predicting anti-PD-1 responders in malignant melanoma from the frequency of S100A9+ monocytes in the blood

BACKGROUND: While programmed cell death receptor 1 (PD-1) blockade treatment has revolutionized treatment of patients with melanoma, clinical outcomes are highly variable, and only a fraction of patients show durable responses. Therefore, there is a clear need for predictive biomarkers to select pat...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Immunother Cancer
Hauptverfasser: Rad Pour, Soudabeh, Pico de Coaña, Yago, Demorentin, Xavier Martinez, Melief, Jeroen, Thimma, Manjula, Wolodarski, Maria, Gomez-Cabrero, David, Hansson, Johan, Kiessling, Rolf, Tegner, Jesper
Format: Artigo
Sprache:Inglês
Veröffentlicht: BMJ Publishing Group 2021
Schlagworte:
Clinical/Translational Cancer Immunotherapy
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8108662/
https://ncbi.nlm.nih.gov/pubmed/33963011
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-002171
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge